Fintel reports that on December 23, 2025, Oppenheimer initiated coverage of Aardvark Therapeutics (NasdaqGS:AARD) with a Outperform recommendation.
Analyst Price Forecast Suggests 127.45% Upside
As of December 21, 2025, the average one-year price target for Aardvark Therapeutics is $33.09/share. The forecasts range from a low of $18.18 to a high of $52.50. The average price target represents an increase of 127.45% from its latest reported closing price of $14.55 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.94.
What is the Fund Sentiment?
There are 110 funds or institutions reporting positions in Aardvark Therapeutics. This is an increase of 25 owner(s) or 29.41% in the last quarter. Average portfolio weight of all funds dedicated to AARD is 0.09%, an increase of 49.45%. Total shares owned by institutions increased in the last three months by 5.56% to 9,631K shares.
What are Other Shareholders Doing?
Decheng Capital holds 3,917K shares representing 17.99% ownership of the company. No change in the last quarter.
Citadel Advisors holds 1,360K shares representing 6.25% ownership of the company. In its prior filing, the firm reported owning 1,284K shares , representing an increase of 5.60%. The firm decreased its portfolio allocation in AARD by 8.74% over the last quarter.
Laurion Capital Management holds 1,050K shares representing 4.82% ownership of the company. In its prior filing, the firm reported owning 989K shares , representing an increase of 5.78%. The firm decreased its portfolio allocation in AARD by 0.62% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 350K shares representing 1.61% ownership of the company. In its prior filing, the firm reported owning 175K shares , representing an increase of 50.00%. The firm increased its portfolio allocation in AARD by 84.79% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 337K shares representing 1.55% ownership of the company. In its prior filing, the firm reported owning 34K shares , representing an increase of 89.87%. The firm increased its portfolio allocation in AARD by 1,486.09% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
